The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.

As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.

Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market rebounded toward pre-COVID-19 levels in Q320 as the numbers of hernia and breast surgeries came closer to normal levels. The recovery was somewhat uneven, with Breast Matrices still off -8.6% YoY, while Hernia Matrices were closer to pre-COVID-19 levels, off -2.5% YoY.

As hospitals began to establish a new normal in the time of COVID-19, the US Surgical Matrices Market rebounded to lose only -4.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* (formerly Allergan) held on to its lead despite the effects of the pandemic, as its breast-heavy portfolio showed a slower return to normal. Becton Dickinson* (BD) lost less than AbbVie/Allergan, declining –3.5% YoY, as hernia procedures bounced back to normal levels a little faster.

Among the many topics covered in the comprehensive Q320 US Surgical Matrices Market Recap* are:

Headwinds increased in Q2 as COVID-19 shut down elective procedures and stay-at-home orders impacted trauma volumes, but by the end of the quarter tailwinds picked up and it was smooth flying.

Q220 started out in a stall and continued to nosedive, as the Trauma segment experienced decreased admissions in April and May due to stay at home orders that caused a decrease in daily activities, including limited driving for most of the US. The US Trauma Market was down -14.2% YoY, with WW revenues declining -16.2%.

In June tailwinds picked up as stay at home orders began to lift and activities resumed, which boded well for the Trauma segment. Trauma procedures started to rebound in June, as most hospitals resumed surgeries depending upon PPE and OR time and resources. 

Among the many topics covered in the comprehensive Q220 Trauma Market Recap* are:

The US Surgical Matrices Market collapsed in Q220, achieving sales of $227.3MM, off -39.4% YoY, as the effects of COVID-19 became evident with many delayed or canceled surgeries. The problems were evident everywhere, where Breast Matrices dropped -46.4 YoY to $69.6MM in Q220, while Hernia Matrices fell off -35.7% YoY to $157.7MM.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Surgical Matrices Market yielded -39.4% YoY, according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan* held on to its lead despite the effects of the pandemic, giving back -46.9%. Becton Dickinson* (BD) lost less than Allergan, declining -36.8%. However, Medtronic* announced that its hernia business was recovering faster than it expected.

Among the many topics covered in the comprehensive Q220 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants dropped precipitously by -32.4% YoY in Q220, as the effects of COVD-19 became evident with many delayed or canceled surgeries.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Hemostats and Sealants market dropped -32.4% in Q220 according to SmartTRAK Financial Dashboard, a decrease that was presaged in Q120 earnings reports. Baxter* led the decline in Q220, down -42.1% YoY, with the Company’s sealants experiencing the worst YoY shrinkage. Cryolife* was close behind as its BioGlue* franchise saw cardiac surgeries postponed nationwide. In Q220, Ethicon* remained the market leader, followed by Baxter.

Among the many topics covered in the comprehensive Q220 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market treaded water in Q120, up +1.6%, as the impact of COVID-19 began to be felt broadly at the end of a quarter that had initially started with good growth.

In Q120, the US Surgical Matrices Market grew +1.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan* maintained its lead despite the slowdown in breast augmentation and reconstruction surgeries due to COVID-19, gaining +3.4% YoY. Becton Dickinson* (BD) also had been growing well until COVID-19 slowed hernia surgeries, and, like many other companies, warned that Q220 would be far worse since the impact of COVID-19 would be felt at the beginning of the quarter.

Among the many topics covered in the comprehensive Q120 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants grew +6.1% YoY in Q120, up from the pace of Q419 despite the late appearance of COVD-19 in the last few weeks of the quarter. Growth was slightly higher in the Hemostats market, with +6.8% growth driven by relative strength in thrombin hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market had a growth rate of +6.1% in Q120. Leading the way in Q120 was Baxter* with +11.6% YoY growth and continued strength from Tisseel* and Artiss* fibrin sealants. Becton Dickinson* (BD) also posted strong gains as its relaunched Progel* and continued its resurgence in Q120. However, all manufacturers predicted that second-quarter results would be much worse since the full effect of surgery deferrals would be felt for the entire quarter. Some manufacturers warned that revenues were reduced as much as...

Among the many topics covered in the comprehensive Q120 Hemostats and Sealants Market Recap* are:

The US market for Hemostats and Sealants grew +5.8% YoY in Q419, comparable to its +6.2% growth in Q319, with continued strength in fibrin sealants and good growth in absorbable hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market maintained a solid growth rate of +5.8% in Q419 and grew +5.7% YoY. Leading the way in Q419 was Becton Dickinson (BD),  as its relaunch of Progel continued its resurgence. Baxter also posted strong gains.

Among the many topics covered in the comprehensive Q419/FY19 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market showed robust growth in Q419, improving on Q319. Breast matrices rebounded from its Q319 malaise, while hernia matrices grew YoY.

• Q419 Breast Matrices market found its groove again, up YoY. For FY19 Breast Matrices grew well, despite several weak quarters.
• Q419 US Hernia Matrices market increased its growth, with the highest growth rate in biosynthetics and with both xenografts and allografts showing surprising strength. For the year, Hernia Matrices edged up.
• Allergan beat its supply constraints and maintained its leadership of the Breast Matrices market, as Alloderm returned to the market in force. For the full year, Allergan slid due to those Alloderm supply problems.
• BD maintained its No. 1 position in the Q419 Hernia Matrices market.

Among the many topics covered in the comprehensive Q419/FY19 US Surgical Matrices Market Recap* are:

A panel session at ACS Clinical Congress 2019 examines the evidence behind currently proposed techniques to prevent incisional hernias after midline laparotomy closure, including the use of prophylactic mesh and small-bite 4:1 suture closure.

At the American College of Surgeons (ACS) Clinical Congress 2019, there was an important session in which panelists discussed the advantages and disadvantages of using prophylactic mesh after closure of midline laparotomies to prevent incisional hernias. Ajita Prabhu, MD and Benjamin Poulose, MD moderated the panel session on October 28, 2019.

Heidi Miller, MD of University of New Mexico gave background on risk factors for incisional hernias, which she estimated at 12-13% incidence after closure of a laparotomy. She characterized incisional hernias as “mostly due to technical failures,” including poor wound hemostasis or coagulopathy, too much inflammation of the wound and the associated abnormal collagen structure, and sutures without proper tension. With respect to the latter topic, she described how she likes to view the hernia as a chronic wound, with proliferation and remodeling dependent on proper tension of approximation. She also described modifiable risk factors associated with the patient. Smoking and diabetes affect tissue perfusion, with strong data supporting tissue ischemia associated with smoking. Tissue perfusion greatly affects wound healing, as do modifiable factors that affect inflammation, including proper wound care, nutrition (especially vitamin A intake) and obesity, which is associated with chronic inflammation. Additionally, obesity is also associated with increased risk of wound dehiscence and increased mechanical stress tending to open the wound ...